Open AccessProteomics Research to Discover Markers: What Can We Learn from Netflix®?
Author(s) -
David F. Ransohoff
Publication year - 2009
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2009.126698
Subject(s) - data science , field (mathematics) , computer science , strengths and weaknesses , competition (biology) , food and drug administration , quality (philosophy) , clinical study design , proteomics , research design , cancer drugs , clinical trial , cancer , medicine , risk analysis (engineering) , psychology , statistics , pathology , gene , epistemology , social psychology , chemistry , biochemistry , philosophy , mathematics , pure mathematics , biology , ecology
Research in the field of proteomics to discover markers for detection of cancer has produced disappointing results, with few markers gaining US Food and Drug Administration approval, and few claims borne out when subsequently tested in rigorous studies. What is the role of better mathematical or statistical analysis in improving the situation?
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom